Clinical News

Regional Commissioning Workshops

Monday, 21 March 2016 11:52

Your clinical team are invited to meet your commissioners at a regional interactive half-day workshop:

Achieve a Winning Business Case to Improve Outcomes in Gastroenterology & Hepatology Services – An Action Plan

BIRMINGHAM Friday 6th May 8.30am-12.40pm Chair Dr Rupert Ransford
At University of Birmingham, Hornton Grange, 53 Edgbaston Park Rd, Edgbaston B15 2RS (free onsite parking)

MANCHESTER Wednesday 18th May 8.30am-12.40pm Chair: Dr Yeng Ang
Venue TBC

LONDON Friday 20th May 9am-1.15pm Chair: Dr A Frank Muller At Broadway House, Tothill Street London SW1H 9NQ

EAST OF ENGLAND Thursday 12th May 5.30pm-8.10pm Chair Dr Andrew Douds
At Bedford Lodge, Bury Road, Newmarket, CB8 7BX

The BSG has arranged a series of interactive, multi-disciplinary half day workshops for you to help address the challenges many of us are facing in developing our Gastroenterology and Hepatology services. Successful developments seem to occur when Clinicians and the wider Clinical Team work with local Commissioners to agree plans and how they can be funded. Please find the programme and registration form above. The BSG has fully supported this workshop as it is considered to be very important in enabling the developments that we all need to improve the standard of care of our patients.

The objectives are to understand your commissioners' priorities, new NHS developments, identify your service challenges, how to redesign you care pathways and begin to develop a winning business case and action plan with your Commissioners and patients.

CLINICAL TEAMS ATTEND / INVITE LOCAL COMMISSIONERS

To ensure the workshops are truly helpful for you we are asking you to bring along your Clinical Teams (e.g. clinical and nurse leads, hospital business and service managers) and invite your local CCG and Specialised Commissioners so you can discuss the challenges, priorities and actions to redesign your services.

Please find attached a suggested template email for you to invite your local commissioners to join you at this half day workshop. You will also need to attach the workshop programme.

NATIONAL ACTION PLAN REPORT

The series of workshops will culminate with a National Action Plan recommending the key actions for you and your commissioners to improve your services. This will be launched at the BSG Annual Conference on 23rd June 2016 and copies will be sent FREE to all delegates.

We do hope you will be able to join us at this important meeting; please complete the registration form at the end of the programme and return it FREEPOST to Medical Management Services (UK) Ltd, the workshop organisers or simply register at www.medman.co.uk/workshops.

We would also like to thank both Norgine Ltd and Takeda Ltd whose funding have made these meetings possible.

IBD Registry News - March 2016

Tuesday, 01 March 2016 13:25

Latest data submission

We now have information from 11 hospitals on 12,246 IBD patients (up from 8 hospitals and 8,037 IBD patients last quarter). 3 additional teams have registered with HSCIC, so are ready to contribute their data next time.

We're making steady progress with participation and importantly, we have now successfully uploaded data not only from sites using the IBD Registry Patient Management System (PMS) but also sites using the Emis system, 2 web tool sites and one hospital using an in-house database, demonstrating the infrastructure for all the different data capture options. That infrastructure will also allow us to deliver other projects.

The Registry is currently recruiting a Data Manager who will enable us to begin providing a standard report back to sites when we receive their data. Meanwhile, Keith Bodger and his team at Aintree are busy analysing the Hospital Episode Statistics (HES) for IBD as part of a Crohn's and Colitis UK research project. We will begin to see some of the results of this analysis soon; later in the year we will extract the HES data for all patients in the Registry database and be able to analyse the demographics, clinical and HES history for that group.

Colleagues at the sites have worked really hard to upload their data on time - thank you to everyone. We are happy to help any IBD team that needs support to begin collecting and submitting their data. Please contact This e-mail address is being protected from spambots. You need JavaScript enabled to view it if you have any queries at all.

Regional meetings update

We've almost completed our initial series of regional meetings and have now met and developed action plans with over 170 members of IBD clinical teams across the country. Slides from the meetings are at http://ibdregistry.org.uk/workshops/

The Scottish regional meeting will take place in Glasgow on Wednesday 20th April and will be chaired by Dr Ian Arnott. We'd really encourage you to come along, and to bring your team if you can. There is no charge to attend, thanks to support from Tillotts, Takeda, Janssen and Shire. For more information and to register please go to http://ibdregistry.org.uk/

IBD Audit news

As you may know, there is an exciting future ahead for IBD services in the UK. The UK IBD Audit as you know it is moving towards an improved system for data capture and quality improvement, using the IBD Registry. This new programme of work remains on both the quality accounts list and the national clinical audit and patient outcomes programme (NCAPOP) in England. Your ongoing participation is very important, and you'll be hearing from the IBD Audit team at the RCP very soon, with a registration form for you to sign up to join this new initiative.

To find out more about joining the Registry click here or email This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Treatment Recommendations for the management of patients with Chronic HCV Infection

Wednesday, 10 February 2016 12:48

These recommendations were developed at a consensus meeting of clinicians and interested parties on 5 January 2016. Therapies that are NICE approved are presented in bold and those that are NICE unapproved are italicised.

The prices of the different regimens vary considerably. Clinicians should use the most cost effective treatment option taking account of the individual patient's requirements.

BSG Guidance on the Use of Biosimilar Infliximab CT-P13 in IBD

February 2016

Introduction: Dr AB Hawthorne, Chair BSG IBD Section Committee

The infliximab biosimilar CT-P13 (Remsima or Inflectra) received marketing authorisation in June 2013.The drug is now widely used in the treatment of inflammatory bowel disease. There is sufficient data from observational studies to show that safety and clinical efficacy of CT-P13 are comparable to the originator drug, with similar immunogenicity.

Recommendations

  1. Infliximab must be prescribed by brand name (ie Remicade, Remsima or Inflectra) and not by International Non-proprietary Name (INN).
  2. For patients starting infliximab: Remicade, Remsima or Inflectra can be prescribed, taking into account the evidence showing similar clinical effectiveness. There is evidence that monitoring of patients, including measurement of drug and anti-drug antibody levels, is no different for the biosimilar drugs compared to Remicade. The choice of preparation should take into account the cost of the drug and its administration.
  3. There is sufficient evidence to recommend that patients who are in a stable clinical response or remission on Remicade therapy can be switched to Remsima or Inflectra at the same dose and dose interval. This should be done after discussion with individual patients, with explanation of the reason for switching (which is usually on the grounds of benefit to the overall service by reduction in costs of the drug and its administration).
  4. Automatic substitution, (dispensing one medicine instead of another equivalent and interchangeable medicine at the pharmacy level without consulting the prescriber), is not appropriate.
  5. Pharmacovigilance is essential for any new biological medicine, and patients prescribed Remsima or Inflectra should be followed for safety, in a registry such as the UK National IBD Registry.

This document replaces the previous BSG guidance on Biosimilar drugs - IBD Section Statement on Biosimilar drugs (2014) (View here)

Page 2 of 8